Credit: Shutterstock. Findings showed faricimab was associated with rapid drying of retinal fluid. The Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application ...

‒ Post-hoc analyses from four Phase III studies indicate Vabysmo dried retinal fluid faster with fewer injections in wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – ‒ ...

Researchers also suggest potential new genetic associations with macular edema, which warrant further research. A study published in Scientific Reports confirmed previously identified retinal ...

Credit: Shutterstock. Tarcocimab tedromer is an investigational VEGF inhibitor designed to improve bioavailability and intraocular half-life using the Company’s antibody biopolymer conjugate platform.

Diabetic macular edema (DME) is an eye condition that can lead to vision loss in people with diabetes. It occurs as a result of diabetic retinopathy — damaged blood vessels in the eyes due to elevated ...

Panelists discuss how trial findings for aflibercept 8 mg and faricimab in RVO demonstrate comparable efficacy and durability ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

New data from a phase 3 trial measuring Roche’s Vabysmo versus Regeneron and Bayer’s Eylea in retinal vein occlusion (RVO) shows that more patients on Vabysmo had an absence of blood vessel leakage in ...

If approved, EYLEA HD would be the first and only treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period – halving the number of injections that are indicated ...